<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="62158"><DrugName>cholic acid (oral capsule, bile acid metabolism deficits/peroxisomal disorders), Retrophin</DrugName><DrugNamesKey><Name id="43060437">Cholbam</Name><Name id="43121452">Cholic Acid FGK</Name><Name id="43074219">Kolbam</Name><Name id="155696">cholic acid</Name></DrugNamesKey><DrugSynonyms><Name><Value>cholic acid</Value><Types><Type>USAN</Type></Types></Name><Name><Value>cholic acid (oral capsule, bile acid metabolism deficits), Asklepion</Value></Name><Name><Value>Xebam</Value></Name><Name><Value>cholic acid (oral capsule, bile acid metabolism deficits/peroxisomal disorders), Asklepion</Value></Name><Name><Value>cholic acid (oral capsule, bile acid metabolism deficits/peroxisomal disorders), Retrophin</Value></Name><Name><Value>Cholbam</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Kolbam</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Cholic Acid FGK</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>81-25-4</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1041547">Asklepion Pharmaceuticals LLC</CompanyOriginator><CompaniesPrimary><Company id="1069812">Retrophin Inc</Company><Company id="1099619">Orpharma Pty Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="1041547">Asklepion Pharmaceuticals LLC</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1041547" type="Company"><TargetEntity id="5035525895" type="organizationId">Asklepion Pharmaceuticals LLC</TargetEntity></SourceEntity><SourceEntity id="1069812" type="Company"><TargetEntity id="5037453429" type="organizationId">Retrophin Inc</TargetEntity></SourceEntity><SourceEntity id="1099619" type="Company"><TargetEntity id="5043449621" type="organizationId">Orpharma Pty Ltd</TargetEntity></SourceEntity><SourceEntity id="2898" type="ciIndication"><TargetEntity id="E71.5" type="ICD10"></TargetEntity><TargetEntity id="D018901" type="MeSH"></TargetEntity><TargetEntity id="68373" type="ORPHANET"></TargetEntity><TargetEntity id="-1391769030" type="omicsDisease"></TargetEntity><TargetEntity id="1508" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="636" type="ciIndication"><TargetEntity id="10062018" type="MEDDRA"></TargetEntity><TargetEntity id="D008664" type="MeSH"></TargetEntity><TargetEntity id="-721510301" type="omicsDisease"></TargetEntity><TargetEntity id="1374" type="siCondition"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Inborn error of metabolism - US - Apr-2015</FirstLaunched><FirstLaunched>Peroxisome disease - US - Apr-2015</FirstLaunched></PhaseHighestDetailed><RegulatoryDesignations><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="2898">Peroxisome disease</Indication><Indication id="636">Inborn error of metabolism</Indication></IndicationsPrimary><ActionsSecondary><Action id="863">Bile acid modulator</Action></ActionsSecondary><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology></Technologies><LastModificationDate>2019-06-07T13:49:19.000Z</LastModificationDate><ChangeDateLast>2018-06-25T00:00:00.000Z</ChangeDateLast><AddedDate>2009-01-02T10:50:36.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1069812" linkType="Company"&gt;Retrophin&lt;/ulink&gt;, under license from &lt;ulink linkID="1041547" linkType="Company"&gt;Asklepion Pharmaceuticals&lt;/ulink&gt;, has developed and launched oral cholic acid capsules (Xebam; Cholbam; Kolbam; Cholic Acid FGK)  [&lt;ulink linkID="951609" linkType="Reference"&gt;951609&lt;/ulink&gt;], [&lt;ulink linkID="973703" linkType="Reference"&gt;973703&lt;/ulink&gt;], [&lt;ulink linkID="1642728" linkType="Reference"&gt;1642728&lt;/ulink&gt;],  [&lt;ulink linkID="1625818" linkType="Reference"&gt;1625818&lt;/ulink&gt;], [&lt;ulink linkID="1651594" linkType="Reference"&gt;1651594&lt;/ulink&gt;].   In the US, the product is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects and adjunctive treatment of peroxisomal disorders, including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat soluble vitamin absorption [&lt;ulink linkID="1997409" linkType="Reference"&gt;1997409&lt;/ulink&gt;]. In the EU, the product is indicated for the treatment of inborn errors in primary bile acid synthesis due to sterol 27-hydroxylase (presenting as cerebrotendinous xanthomatosis, CTX) deficiency, 2- (or alpha-) methylacylCoA racemase (AMACR) deficiency or Cholesterol 7alpha-hydroxylase (CYP7A1) deficiency in infants, children and adolescents aged 1 month to 18 years and adults [&lt;ulink linkID="1997505" linkType="Reference"&gt;1997505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By April 2015, the drug, as Cholbam, was launched for the treatment of bile acid synthesis disorders and peroxisomal disorders, in pediatric and adult patients in the US  [&lt;ulink linkID="1651594" linkType="Reference"&gt;1651594&lt;/ulink&gt;]. In March 2017, it was noted that  the drug, as Kolbam, was being sold internationally, so it is presumed that by that time, the drug had been launched in the EU since at that time,  the company was working to secure pricing and reimbursement approval for the product in the EU [&lt;ulink linkID="1997537" linkType="Reference"&gt;1997537&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2017, Retrophin stated that following Orphan Drug designation in the US, the product was expected to have marketing exclusivity in the US for approved  indications until March 2022.  The company expected marketing exclusivity in Europe for the approved  indications until September 2024 [&lt;ulink linkID="1997537" linkType="Reference"&gt;1997537&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;&lt;subtitle&gt;The US&lt;/subtitle&gt;By January 2015, the product had  presumably been filed in the US as it was in a late-stage review by the US FDA  [&lt;ulink linkID="1625818" linkType="Reference"&gt;1625818&lt;/ulink&gt;]. By March 2015, the drug had been granted a rare pediatric disease Priority Review voucher by the FDA. At that time, the FDA approved the drug, as Cholbam, for the treatment of bile acid synthesis disorders due to single enzyme defects, and peroxisomal disorders including Zellweger spectrum disorders, in pediatric (aged 3 weeks and older) and adult patients. The FDA stated that an observational study to evaluate the long-term safety of the drug was required post-approval [&lt;ulink linkID="1642728" linkType="Reference"&gt;1642728&lt;/ulink&gt;], [&lt;ulink linkID="2018103" linkType="Reference"&gt;2018103&lt;/ulink&gt;]; by April 2015, the drug had been made available in the US  [&lt;ulink linkID="1651594" linkType="Reference"&gt;1651594&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2003, the drug was granted Orphan drug designation in the US for the treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for patients with peroxisomal disorders [&lt;ulink linkID="1997537" linkType="Reference"&gt;1997537&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Europe&lt;/subtitle&gt;In March 2012, an MAA was filed in the EU for the treatment of inborn errors of primary bile acid synthesis responsive to treatment with cholic acid; the filing claimed nine therapeutic indications, which was later reduced to five [&lt;ulink linkID="2003699" linkType="Reference"&gt;2003699&lt;/ulink&gt;], [&lt;ulink linkID="1282741" linkType="Reference"&gt;1282741&lt;/ulink&gt;]. In November 2013, the CHMP of the  EMA recommended that two of the five indications were not approvable due to their similarity to those of &lt;ulink linkID="1088756" linkType="Company"&gt;Laboratoires CTRS&lt;/ulink&gt;'s approved Orphan cholic acid medication &lt;ulink linkID="87819" linkType="Drug"&gt;Orphacol&lt;/ulink&gt;; the filer withdrew those indication from the MAA. In  November 2013, the CHMP recommended approval of the drug for the treatment of inborn errors of primary bile acid synthesis due to sterol-27 hydroxylase deficiency (CTX), 2- (or alpha-) methylacyl-CoA racemase (AMACR) deficiency or cholesterol 7alpha-hydroxylase (CYP7A1) deficiency, and in April 2014, the drug was approved in the EU [&lt;ulink linkID="2003699" linkType="Reference"&gt;2003699&lt;/ulink&gt;]. In June 2015, the MAA was annulled, following a court judgment in a lawsuit brought by Laboratoires CTRS against the European Commission. In September 2015, the CHMP adopted a revised opinion, recommending granting of an MAA under exceptional circumstance for the treatment of inborn errors in primary bile acid synthesis due to deficiencies in specific liver enzymes: sterol 27-hydroxylase (presenting as CTX) deficiency, 2-AMACR deficiency, or CYP7A1 deficiency [&lt;ulink linkID="1726860" linkType="Reference"&gt;1726860&lt;/ulink&gt;]. In November 2015,  the product, as Kolbam, was approved in the EU in that setting in infants, children and adolescents aged 1 month to 18 years and in adults [&lt;ulink linkID="1726841" linkType="Reference"&gt;1726841&lt;/ulink&gt;]. In March 2017, it was noted that  the drug, as Kolbam, was being sold internationally, so it is presumed that by that time, the drug had been launched in the EU since at that time,  the company was working to secure pricing and reimbursement approval for the product in the EU [&lt;ulink linkID="1997537" linkType="Reference"&gt;1997537&lt;/ulink&gt;]. In April 2017, the EMA's CHMP re-assessed the MAA and decided it would remain under exceptional circumstances [&lt;ulink linkID="1947264" linkType="Reference"&gt;1947264&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In October 2009, cholic acid was granted Orphan status for  the treatment of inborn errors of primary bile acid synthesis [&lt;ulink linkID="1285316" linkType="Reference"&gt;1285316&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rest of the world&lt;/subtitle&gt;&lt;subtitle&gt;Asia Pacific&lt;/subtitle&gt;In July 2016, the drug (as Cholbam; Kolbam) was granted Orphan Drug status in Taiwan as an adjunctive treatment for peroxisomal disorders, including Zellweger spectrum disorders [&lt;ulink linkID="1941145" linkType="Reference"&gt;1941145&lt;/ulink&gt;], [&lt;ulink linkID="1941147" linkType="Reference"&gt;1941147&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2013, the  Australian TGA approved an application for Orphan drug designation, submitted by Australian licensee &lt;ulink linkID="1099619" linkType="Company"&gt;Orpharma&lt;/ulink&gt;, for the treatment of inborn errors of bile acid synthesis responsive to treatment with cholic acid [&lt;ulink linkID="1646449" linkType="Reference"&gt;1646449&lt;/ulink&gt;], [&lt;ulink linkID="1646446" linkType="Reference"&gt;1646446&lt;/ulink&gt;]. In January 2018, a filing, presumed to be in Australia, was  expected   in the coming months [&lt;ulink linkID="1997856" linkType="Reference"&gt;1997856&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Postmarketing><displayLabel>Postmarketing</displayLabel><value>&lt;Postmarketing&gt;&lt;para&gt;In March 2015, the FDA required that an observational study to evaluate the long-term safety of the drug post-approval [&lt;ulink linkID="1642728" linkType="Reference"&gt;1642728&lt;/ulink&gt;]. In June 2017, a prospective, observational, non-interventional, post-marketing, patient registry (&lt;ulink linkID="294977" linkType="Protocol"&gt;NCT03115086&lt;/ulink&gt;; 031CHO15001; REPLACE) commenced in the US to document long-term safety and clinical outcomes  in patients (expected n = 110) treated or newly starting treatment with cholic acid at enrollment. The coprimary endpoints included the incidence of new-onset or worsening cholestasis, steatorrhea leading to poor growth, changes in serum fat soluble vitamin levels, growth failure and treated-related adverse events. At that time, the registry was expected to complete in August 2030 [&lt;ulink linkID="1997476" linkType="Reference"&gt;1997476&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Postmarketing&gt;</value></Postmarketing><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In September 2011, a non-randomized, open-label, single-center, phase III trial (&lt;ulink linkID="81026" linkType="Protocol"&gt;NCT01438411&lt;/ulink&gt;; CAC-002-01) was initiated   in the US in patients (expected n = 45) with inborn errors of bile acid synthesis, to assess the safety and efficacy of cholic acid capsules. The primary endpoint was the change from baseline in atypical bile acid metabolites. The study completed in  August 2016 [&lt;ulink linkID="1228000" linkType="Reference"&gt;1228000&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2008, Asklepion commenced phase III trials for the treatment of inborn errors of bile acid metabolism  [&lt;ulink linkID="973703" linkType="Reference"&gt;973703&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 1992, a non-randomized, open-label, single-group-assignment, phase III trial (&lt;ulink linkID="81028" linkType="Protocol"&gt;NCT00007020&lt;/ulink&gt;; CAC-91-10-10; CCHMC-91-10-10; NCRR-M01RR08084-0009) was initiated in the US, patients (n = 79) with  inborn errors of bile acid synthesis and metabolism, to assess the safety and efficacy of cholic acid capsules. The trial commenced as an investigator-led trial with a single study site that was expanded in 2005 for compassionate use. The study was completed in December 2009 [&lt;ulink linkID="1632392" linkType="Reference"&gt;1632392&lt;/ulink&gt;]. By March 2015, the trial had been conducted in patients (n = 50) with bile acid synthesis disorders due to single enzyme defects. An extension trial followed 21 patients from the uncontrolled trial and enrolled an additional 12 patients. At that time, interim efficacy data from the 12 patients were available for an additional 21 months. In 64% of the patients, improvement in baseline liver function tests and weight was observed. Two-thirds of patients survived for more than three years. By that time, the trial included patients (n = 29) with peroxisomal disorders, including Zellweger spectrum disorders. An extension trial followed 10 patients from the uncontrolled trial and enrolled an additional two patients. At that time, interim efficacy data from the 2 patients were available for an additional 21 months. In 46% of the patients, improvement in baseline liver function tests and weight was observed. A total of 42% of patients survived for more than three years    [&lt;ulink linkID="1642728" linkType="Reference"&gt;1642728&lt;/ulink&gt;]. In September 2017, results were published. A total of 79 patients received at least one dose of study medication with 70 patients (50 with single enzyme defect and 20 with Zellweger spectrum disorder) included in the modified intent-to-treat dataset. Cholic acid administered po (10 to 15 mg /kg /day) significantly improved urine bile acid metabolite scores (p &amp;lt;  0.0001) and serum aspartate aminotransferase and alanine aminotransferase (p &amp;lt;  0.0001) levels. In both groups, improvement in height and weight percentiles was observed with cholic acid, but only the change in weight was found to be significant (p &amp;lt;  0.05). Serum direct bilirubin decreased significantly post-treatment (p &amp;lt;  0.001), and liver biopsies showed either stable findings or histological improvement in all parameters except bridging fibrosis [&lt;ulink linkID="1968853" linkType="Reference"&gt;1968853&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1069812">Retrophin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-17T00:00:00.000Z</StatusDate><Source id="1651594" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1069812">Retrophin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-04-17T00:00:00.000Z</StatusDate><Source id="1651594" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1069812">Retrophin Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2017-03-01T00:00:00.000Z</StatusDate><Source id="1997537" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1099619">Orpharma Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</StatusDate><Source id="1646449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1099619">Orpharma Pty Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</StatusDate><Source id="1646449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1069812">Retrophin Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1069812">Retrophin Inc</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-22T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="2011287" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</StatusDate><Source id="1646449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="2011287" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="2011287" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</StatusDate><Source id="1646449" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2008-06-17T00:00:00.000Z</StatusDate><Source id="973703" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="EU">EU</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2012-03-21T00:00:00.000Z</StatusDate><Source id="2003699" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-12T00:00:00.000Z</StatusDate><Source id="1625818" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-17T00:00:00.000Z</StatusDate><Source id="1642728" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-17T00:00:00.000Z</StatusDate><Source id="1642728" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1069812">Retrophin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="2011287" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1069812">Retrophin Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-31T00:00:00.000Z</StatusDate><Source id="2011287" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-10-28T00:00:00.000Z</StatusDate><Source id="1285316" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-01-12T00:00:00.000Z</StatusDate><Source id="1625818" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-07-31T00:00:00.000Z</StatusDate><Source id="1997537" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2898">Peroxisome disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-07-31T00:00:00.000Z</StatusDate><Source id="1997537" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-04T00:00:00.000Z</StatusDate><Source id="2003699" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1069812">Retrophin Inc</Company><Country id="EU">EU</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="636">Inborn error of metabolism</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-11-20T00:00:00.000Z</StatusDate><Source id="1726841" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1041547">Asklepion Pharmaceuticals LLC</OwnerCompany><Country id="TW">Taiwan</Country><Indication id="2898">Peroxisome disease</Indication><AwardedIndication>Treatment of peroxisomal disorders including Zellweger spectrum disorders</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2016-07-22T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-05-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-11-30T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="6">Maintenance Recommendation</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2014-04-24T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1099619">Orpharma Pty Ltd</OwnerCompany><Country id="AU">Australia</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors of bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-07-23T00:00:00.000Z</MileStoneDate><Source id="1646449" type="PR"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="5">Transfer of Ownership</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-12-31T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-10-28T00:00:00.000Z</MileStoneDate><Source id="1285316" type="OTHER"></Source></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="EU">EU</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors in primary bile acid synthesis responsive to treatment with cholic acid</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="2">Positive Opinion</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2009-09-02T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="1">Orphan Drug</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="US">US</Country><Indication id="636">Inborn error of metabolism</Indication><AwardedIndication>Treatment of inborn errors of cholesterol and bile acid synthesis and metabolism</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2003-07-18T00:00:00.000Z</MileStoneDate></Row><Row><RegulatoryDesignation id="13">Rare Pediatric Disease</RegulatoryDesignation><OwnerCompany id="1069812">Retrophin Inc</OwnerCompany><Country id="US">US</Country><Indication id="2898">Peroxisome disease</Indication><AwardedIndication>Treatment of bile acid synthesis disorders due to single enzyme defects, and peroxisomal disorders including Zellweger spectrum disorders</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2015-03-17T00:00:00.000Z</MileStoneDate><Source id="1642728" type="PR"></Source></Row></RegulatoryDesignationStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1041547">Asklepion Pharmaceuticals LLC</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1069812">Retrophin Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1099619">Orpharma Pty Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="14">Drug - Asset Divestment</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C</Smiles></StructureSmiles><Deals><Deal id="152476" title="Retrophin to acquire Asklepion's cholic acid for bile acid synthesis defects worldwide      "></Deal><Deal id="153821" title="Orpharma and Asklepion to develop cholic acid capsules against biliary tract disease  "></Deal></Deals><hasSWOTs>Y</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>